| INTRODUCTION
Sickle cell anemia (SCA) is a qualitative hemoglobinopathy characterized by the substitution of glutamic acid for valine at the sixth codon of the beta chain S globin. 1 This substitution results in the production of an abnormal protein called hemoglobin S (HbS) α 2 β s 2 . The disease is characterized by its extreme clinical heterogeneity.
This clinical polymorphism is influenced by environmental factors and genetic factors. [2] [3] [4] Genetic factors modulators of sickle cell phenotype have been associated with asymptomatic phenotype. These genetic factors include the influence of fetal hemoglobin (HbF) (α 2 γ 2 ) and the association between SCA and alpha-thalassemia.
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The modulator and protective effect of alpha-thalassemia on clinical manifestations of sickle cell anemia is due to the fact that the decrease of the mean corpuscular hemoglobin concentration. The hypochromic anemia resulting from this situation reduces the risk of the polymerization of the HbS. 2 Thalassemic syndromes are very common in malaria-endemic areas. 8 Silent alpha thalassemia form (−α/αα) and cis or trans alphathalassemia minor forms are most encountered in sub-Saharan Africa. 9 These forms are often clinically asymptomatic. 10 The 3.7 kb alpha-globin chain deletion (α 3.7 kb deletion) is a common silent form encountered. [11] [12] [13] In previous studies, the α-triplication was reported with low frequency in sub-Saharan populations. 14 The Democratic Republic of Congo (DRC) has the second highest incidence of SCA patients in Africa after Nigeria. The prevalence of the disease is estimated from 0.97% to 1.4% in newborns and an incidence of SCA is estimated to be 30 000 to 40 000 neonates per year. [15] [16] [17] In Congolese population, the disease is characterized by a low level of fetal hemoglobin and F-Cells, and the risk of developing severe clinical symptomatology.
Despite high prevalence of this hemoglobinopathy in the DRC, information about the association between SCA and alpha thalassemia in population suffering from SCA are unknown. We therefore conducted a cross-sectional study in sickle cell patients living in Kinshasa, the DRC. The objectives of this study were to estimate the prevalence of this association and to assess its influence on clinical and hematological profile in our midst.
| METHODS

| Study design and population
The present cross-sectional study is the first part of a larger ongoing study of genetic overview in sickle cell anemia in the DRC. The study was conducted in Sickle cell center of Yolo/Kalamu in Kinshasa The samples were collected from patients in steady state regularly followed up at the outpatient clinic of Sickle cell center of Yolo. All patients were free of pain for at least 1 month and had not been hospitalized for at least 100 days before the study.
19
We excluded subjects with (i) initiated antibiotics treatment prior to seeking medical care; (ii) previous blood transfusion in the 3 months prior to the study (iii) under hydroxyurea (iv) under chronic transfusion program.
| Data collection procedure and blood analysis
Five milliliters (mL) of venous blood sample were drawn from each study participant into an Ethylenediaminetetraacetic acid (EDTA)
tube, used to determine hematologic parameters. These were determined using an automated Hematology Analyzer Sysmex XS-1000i
(Lincolnshire, IL, USA). Hematological and biochemical analyzes were performed in the laboratory of the Institut National de Recherche 
| DNA extraction
Genomic DNA was extracted from 5 mL of venous blood collected in a tube with EDTA, using the method of "Salting out".
| Diagnosis of sickle cell anemia
Sickle cell screening was performed using semi-automated electrophoresis technique with the Hydrasis II apparatus (Sebia, Lysse, France). The electrophoresis technique separates hemoglobin in acid and alkaline agarose gel. SCA was diagnosed in the presence of production of HbS with no Hb -A. The concentrations were measured by an integrated densitometer.
| Confirmation of the diagnosis of sickle cell anemia
The DNA was concentrated to 50 ηg/μL with a robot dropsence (Trinean NV, Gand, Belgium).
The diagnosis of sickle cell anemia was confirmed with a molecular test with a molecular test using PCR-RFLP technique. This 
| The diagnosis of thalassemia
The diagnosis of thalassemia was performed by the technique of multiplex ligation dependent probe amplification (MLPA). The analysis was performed using the SALSA MLPA kit P140 probemix HBA provided by MRC-Holland (Amsterdam, the Netherlands). The various alpha-thalassemia deletions were categorized according to the ratios of the probes of the deletion area ( 
| Ethical considerations
All major participants provided written consent for study participa- Anonymity of the participants was guaranteed and no personal details were recorded.
| Data management and analysis
Data are represented as means±standard deviation (SD) when the distribution was normal or median with range when the distribution was not normal. Frequency of various clinical and laboratory findings are expressed as percentages. The confidence interval at 95% was calculated. Associations between variables and subtypes of polymorphisms were evaluated using chi-square and fisher exact test. A P value <.05 was considered significant.
| Role of the funding source
None of the funders had involvement in the study design, data collection, data analysis, data interpretation, writing of the report, or access to all the data in the study and had the final responsibility for the decision to submit for publication.
| RESULTS
The mean age of our patients was 22.4±13.6 years. The sex ratio female/male was 3.2. 
| Alpha thalassemia polymorphism
| Hematologic parameters in the study population
The Hb and HbF were significantly lower in the group of patients with triplication. Leukocytosis and reticulocytosis were similar in all groups. However, the group of patients with α 3.7 triplication had the lowest rate of platelets with a statistically significant difference.
Mean corpuscular volume (MCV) and mean concentration hemoglobin (MCHC) were significantly lower in the group of patients with homozygous α 3.7 deletion and α 3.7 triplication. Other details are shown in Table 2 .
| Frequency of acute and chronic complications of SCA
The average of severe vasoocclusive crisis (VOC), the rates of blood transfusions per year, the rate of osteonecrosis, cholelithiasis and the rate of leg ulcers were significantly lower in the group of patients with homozygous α 3.7 deletion and α 3.7 triplication (Figures 1-5 ).
| Relationship between alpha-thalassemia polymorphism and microcytosis
Microcytosis was more frequent in sickle cell patients with homozygous deletion (thalassemia minor) and was found in 17 (16.03%) cases.
Microcytosis was a rare event in sickle cell patients with heterozygous α 3.7 heterozygous deletion (1.9%), α 3.7 triplication (0.9%) and also in those with normal α genotype (2.8%).
| DISCUSSION
Alpha-thalassemia associated with SCA has been described as a modulating factor of sickle cell phenotype. 6, 20, 21 Despite the high T A B L E 2 Hematologic characteristics of the study population according to alpha-thalassemia polymorphisms 
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prevalence and incidence of the disease in Central Africa, there is still very little information on alpha-thalassemia in patients suffering from SCA living in this part of the world. 9, [21] [22] [23] This study was the first to be performed specifically in Central Africa where sickle cell anemia is most frequent with a predominance of Bantu haplotype.
Our study showed that association between alpha-thalassemia and SCA is frequent in our midst. Indeed, nearly 49% of sickle cell patients are carriers of a deletional thalassemia. Among them, 25.5%
had a homozygous α 3.7 deletion and 23.6% had a heterozygous α 3.7 deletion. This frequent association between alpha-thalassemia and sickle cell anemia has been reported in several African and Arab-Indian studies. 9, [24] [25] [26] On the other hand, the frequency of α 3.7 triplication observed in this Congolese series is the highest reported compared to worldwide series where the frequencies range from 1.3% to 5%. 24, [27] [28] [29] This difference may be explain by the fact that the frequency of α-triplication varies according to population origin. 30 However, the frequency in non SCA Congolese population is unknown.
We report a lower level of Hb, leukocytes, platelets, HbF, MCV and MCHC in patients with sickle cell anemia with co-existent α 3.7 triplication. Low MCHC and low MCV are described as factors that could reduce morbidity in SCA. 2, 31 The decrease of MCHC is a major factor which reduces the risk of polymerization of HbS, while the low MCV is a factor which improves rheology in SCA patients. 2 Furthermore, it is well known that leukocytosis, thrombocytosis and increased reticulocyte production are major factors of acute sickle cell crises. [31] [32] [33] [34] Thus, the low expression of these disease markers could explain the protective effect of homozygous deletion and triplication on the severity of the SCA.
Our study showed that the annual average of severe VOC and lower blood transfusions were low in patients with α 3.7 triplication and homozygous α 3.7 deletion compared to patients with normal genotype αα/αα and heterozygous α 3.7 deletion. The reduction of VOC and lower blood transfusions may be associated with the modification of hematological parameters changes observed in these two groups.
Indeed, the risk of VOC risk in SCA is increased by the cytoadherence of granulocytes and reticulocytes to endothelium. Additionally, the risk of VOC in SCA is associated with increased cytoadherence of polynuclear and reticulocytes to endothelium, while platelets are involved in VOC by the secretion of thrombospondin.
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Hemolysis in sickle cell disease is often secondary to the process of polymerization and the vaso-occlusion. Chronic complications of hyperhemolysis are gallstone cholecystitis and leg ulcers. 38, 39 In our series, cholelithiasis and leg ulcers were less frequent in groups of patients with α 3.7 triplication and homozygous α 3.7 deletion. Alpha thalassemia was identified as a protective factor against cholelithiasis and leg ulcers. 40 In this report, patients with homozygous α 3.7 deletion and α 3.7 triplication were less likely to develop osteonecrosis of the femoral head compared to other groups. The protective effect of alpha-thalassemia of osteonecrosis is not well established. In a previous study, SCA patients with alpha-gene deletion were at the greatest risk for osteonecrosis. [41] [42] [43] In this series, the protective effect of the homozygous α 3.7 deletion and α 3.7 triplication observed could be associated with the observed hematological changes in these two groups.
These results are in contrast with those of India in which clinical symptoms occurred at higher frequency and were more severe. This difference may be due to the fact that in their series, the authors included patients with α 3.7 triplication in the without α-deletion group of patients. 24 Furthermore, in sickle cell β-thalassemia patients, the presence of an alpha triplication worsens the clinical state. 44 
| CONCLUSION
The prevalence of the association between SCA and alpha thalassemia encountered has been described and the influence on clinical and hematological profile assessed in our midst. In our study, the prevalence of α 3.7 triplication was higher than those reported in worldwide series. The homozygous deletion and triplication were associated with less severe forms of the SCA in Congolese patients. These results
showed the need to investigate systematically the alpha-globin gene mutations in sickle cell population in our midst. Providing data that can properly be used for advocacy as well as for developing further strategies for improving the care of the SCA patients is very important for region with high prevalence of the disease such as the Central Africa.
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